Resistance to the Beneficial Metabolic Effects and Hepatic Antioxidant Defense Actions of Fibroblast Growth Factor 21 Treatment in Growth Hormone-Overexpressing Transgenic Mice

Table 2

FGF21-induced transcriptional changes in hepatic carbohydrate and lipid metabolism.

Gene of interest	N-PBS	N-FGF21	Tg-PBS	Tg-FGF21
Insulin signaling
IR	1 ± 0.17^a	4.68 ± 0.91^b	1.37 ± 0.44^a	1.01 ± 0.12^a
IRS-1	1 ± 0.18^a	3.01 ± 0.63^b	0.53 ± 0.09^a	0.82 ± 0.15^a
IRS-2	1 ± 0.14^a	2.03 ± 0.21^b	1.40 ± 0.34^a	1.19 ± 0.22^a
Gluconeogenesis
PEPCK	1 ± 0.07^a	1.82 ± 0.21^b	0.64 ± 0.19^a	0.54 ± .021^a
G6Pase	1 ± 0.10^a	2.15 ± 0.33^b	0.59 ± 0.20^a	0.63 ± 0.14^a
HNF4	1 ± 0.08^a	2.34 ± 0.45^b	0.79 ± 0.10^a	0.79 ± 0.13^a
HNF1	1 ± 0.16^a	3.54 ± 0.78^b	1.14 ± 0.37^a	1.47 ± 0.44^a
PGC1	1 ± 0.14^a	2.37 ± 0.65^b	0.68 ± 0.09^a	0.88 ± 0.12^a
Lipogenesis
ACC	1 ± 0.12^a	1.75 ± 0.30^b	2.14 ± 0.36^b	2.22 ± 0.40^b
FASN	1 ± 0.15^a	1.94 ± 0.32^b	1.69 ± 0.31^b	1.54 ± 0.26^b
Fatty acid oxidation
CPT1	1 ± 0.19^a	2.62 ± 0.35^b	0.36 ± 0.11^c	0.51 ± 0.09^c
ACOX1	1 ± 0.11^a	2.48 ± 0.28^b	0.49 ± 0.10^c	0.46 ± 0.08^c
UCP2	1 ± 0.13^a	1.90 ± 0.37^b	4.15 ± 1.01^c	4.33 ± 0.88^c
AMPK	1 ± 0.09^a	2.25 ± 0.52^b	0.84 ± 0.12^a	0.95 ± 0.10^a

Shown is RT-PCR analysis of gene expression in normal and GH transgenic mice treated with FGF21 and vehicle (mean ± SEM, = 5). Different superscripts denote significant difference at < 0.05.